In case of a significant impact of the epidemiological crisis that would lead to the stagnation of the national economy, the central consolidated budget’s revenues from taxers, contributions and mandatory insurance premiums would decrease by 2.3 billion lei if the purchasing power of the Moldovan leu remained the same as last year, noted economic expert Viorel Gîrbu, who stated for Infodebit that the national authorities should make effort to minimize the impact of the epidemiological crisis, avoiding its transformation into a long-lasting economic and social crisis, IPN reports.
This is important not only because fiscal incomes could not be collected this year, but also because the enterprises or event strategic sectors of the national economy will return to the level before the crisis in a rather long period of time.
Viorel Gîrbu said the healthcare sector ranks third in the list of priorities for which funds will be allocated from the central consolidated budget. In time this sector underwent changes that influenced the number of medical institutions financed with public funds and the personnel working in the sector.
In 2000-2017, the number of hospitals decreased from 132 to 87, while the number of private hospitals increased. Similarly, the number of medical staff diminished, but this indicator since 2006 has been generally on the rise. This way, the number of doctors per 10,000 people even improved slightly. However, the number of public hospitals in 2006-2017 didn’t undergo essential changes, while the number of beds in hospitals per 10,000 people decreased consistently, declining from 63.2 units in 2012 to 51.9 in 2017. The situation in the private healthcare sector followed even more negative trends.
As to trade in pharmaceutical products, Viorel Gîrbu said that when the domestic market is large, the performance of the national business entities active in the field is modest. The number of companies that manufacture basic pharmaceutical products and pharmaceutical preparations decreased by one third in 2014-2018. The value of the products and services provided by these represented 16% of the total volume of retail trade in pharmaceutical products in 2018.
